These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 25084527

  • 41. New Pharmacological Approaches for Rare Diseases.
    Ortega-Gutiérrez S.
    Int J Mol Sci; 2023 Apr 14; 24(8):. PubMed ID: 37108436
    [Abstract] [Full Text] [Related]

  • 42. Retraction. Transplantation: tolerance (Current Opinion in Investigational Drugs (2003) 4(5):530-535).
    Curr Opin Investig Drugs; 2009 Aug 14; 10(8):882. PubMed ID: 19649932
    [No Abstract] [Full Text] [Related]

  • 43. Global access to biological disease-modifying drugs.
    McCormick R, Hotchkin R, Manson J.
    Lancet Rheumatol; 2022 Jul 14; 4(7):e465. PubMed ID: 38294015
    [No Abstract] [Full Text] [Related]

  • 44. Drugs and Disease.
    Hospital (Lond 1886); 1895 May 25; 18(452):124. PubMed ID: 29809520
    [No Abstract] [Full Text] [Related]

  • 45. Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease.
    Arribat Y, Talmat-Amar Y, Paucard A, Lesport P, Bonneaud N, Bauer C, Bec N, Parmentier ML, Benigno L, Larroque C, Maurel P, Maschat F.
    Acta Neuropathol Commun; 2014 Aug 05; 2():86. PubMed ID: 25091984
    [Abstract] [Full Text] [Related]

  • 46. Prion-like proteins sequester and suppress the toxicity of huntingtin exon 1.
    Kayatekin C, Matlack KE, Hesse WR, Guan Y, Chakrabortee S, Russ J, Wanker EE, Shah JV, Lindquist S.
    Proc Natl Acad Sci U S A; 2014 Aug 19; 111(33):12085-90. PubMed ID: 25092318
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients.
    Skotte NH, Southwell AL, Østergaard ME, Carroll JB, Warby SC, Doty CN, Petoukhov E, Vaid K, Kordasiewicz H, Watt AT, Freier SM, Hung G, Seth PP, Bennett CF, Swayze EE, Hayden MR.
    PLoS One; 2014 Aug 19; 9(9):e107434. PubMed ID: 25207939
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Dysfunction of the CNS-heart axis in mouse models of Huntington's disease.
    Mielcarek M, Inuabasi L, Bondulich MK, Muller T, Osborne GF, Franklin SA, Smith DL, Neueder A, Rosinski J, Rattray I, Protti A, Bates GP.
    PLoS Genet; 2014 Aug 19; 10(8):e1004550. PubMed ID: 25101683
    [Abstract] [Full Text] [Related]

  • 51. Investigational agents for the management of Huntington's disease.
    Müller T.
    Expert Opin Investig Drugs; 2017 Feb 19; 26(2):175-185. PubMed ID: 27927041
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Targets for future clinical trials in Huntington's disease: what's in the pipeline?
    Wild EJ, Tabrizi SJ.
    Mov Disord; 2014 Sep 15; 29(11):1434-45. PubMed ID: 25155142
    [Abstract] [Full Text] [Related]

  • 58. Potential therapeutic targets in polyglutamine-mediated diseases.
    Katsuno M, Watanabe H, Yamamoto M, Sobue G.
    Expert Rev Neurother; 2014 Oct 15; 14(10):1215-28. PubMed ID: 25190502
    [Abstract] [Full Text] [Related]

  • 59. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.
    Süssmuth SD, Haider S, Landwehrmeyer GB, Farmer R, Frost C, Tripepi G, Andersen CA, Di Bacco M, Lamanna C, Diodato E, Massai L, Diamanti D, Mori E, Magnoni L, Dreyhaupt J, Schiefele K, Craufurd D, Saft C, Rudzinska M, Ryglewicz D, Orth M, Brzozy S, Baran A, Pollio G, Andre R, Tabrizi SJ, Darpo B, Westerberg G, PADDINGTON Consortium.
    Br J Clin Pharmacol; 2015 Mar 15; 79(3):465-76. PubMed ID: 25223731
    [Abstract] [Full Text] [Related]

  • 60. Phosphodiesterases as therapeutic targets for Huntington's disease.
    Fusco FR, Giampà C.
    Curr Pharm Des; 2015 Mar 15; 21(3):365-77. PubMed ID: 25159076
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.